Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Cyrille Hulin et al.|Nature Medicine|2024Cited by 109
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast NephropathyFrank Bridoux, Bertrand Arnulf, Lionel Karlin et al.|Journal of Clinical Oncology|2020Cited by 47
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periodsJill Corre, Aurore Perrot, Cyrille Hulin et al.|Leukemia|2021Cited by 41
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Samuel Y. Ng et al.|Blood|2021Cited by 37
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, Cyrille Touzeau et al.|Blood|2025Cited by 34